Multiple ascending dose study of ALKS 7119

1. Willing and able to provide informed consent

2. Capable of understanding and complying with the protocol

3. Male or female adult and ≥18 and ≤45 years of age, inclusive, at screening (Visit 1)

4. Has a body mass index ≥18.0 and ≤32.0 kg/m2 at screening (Visit 1)

5. Agrees to use an acceptable method of contraception from 30 days prior to screening and for 90 days after any study drug administration, or must be surgically sterile or post-menopausal (if female)

1. Clinically significant medical condition or observed abnormalities, in the opinion of the investigator (including, clinically significant physical examination finding, vital sign result, ECG result, laboratory or urinalysis test result) and/or any other finding that, in the investigator’s judgment, could potentially compromise subject safety, or PK or PD evaluation, or affect the subject’s ability to adhere to the protocol visit schedule, or fulfill visit requirements

2. Female subject that is currently pregnant or breastfeeding, or plans to become pregnant or begin breastfeeding at any point during the study and for 90 days after any study drug administration

3. Has a history of intolerance or hypersensitivity to dextromethorphan or any dextromethorphan-containing product

4. Has had a clinically significant illness in the 30 days prior to first study drug administration (Day 1)

5. Has a positive drug screen

6. Has a positive breath test for alcohol at screening (Visit 1) or upon admission (Day -1)

7. Has a positive serology test for hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus antibody (HIVAb) at screening (Visit 1)

8. Has a clinically significant lifetime history of suicidal ideation or suicidal behavior and/or poses a current (within past year) suicide risk, as

9. Has used any prescription or over-the-counter medication, including herbal remedies and nutritional supplements (except vitamins), within 7 days prior to screening (Visit 1) or admission (Day -1)

10. Has ingested any alcohol, caffeine or xanthine within 24 hours prior to inpatient admission (Day -1), or excessive caffeine consumption (defined as ≥800 mg per day) at screening (Visit 1)

11. Has used any product containing nicotine within 30 days prior to admission (Day -1)

12. Has participated in a clinical trial of an investigational product within 3 months prior to screening (Visit 1) or participated in more than four investigational drug studies within 1 year prior to screening (Visit 1)

13. Has previously participated in a clinical trial with ALKS 7119